Climb Bio Inc CLYM
Set alert
10.25 USD -0.08 -0.77%
At close · Oct 30
10.25 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
10.02 Day range 10.51
1.64 52-week range 17.84
- YTD
- +156.25%
- 1 year
- +415.08%
- Open
- 10.29
- Prev close
- 10.33
- Mkt cap
- 588.72M
- Vol
- 708.75K
- Avg vol
- 1.41M
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.02
- High
- 10.51
- Forward P/E
- -16.92
- Beta
- 0.08
- Short ratio
- 5.77
- Inst. own
- 105.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.42
- 200-d avg
- 8.11
- 1y target
- 22.86
2Y chart
Events in this range
- Aug 12, 2025Earnings: -0.13; estimate -0.19; surprise 31.58%
- Nov 6, 2025Earnings: -0.19; estimate -0.16; surprise -18.75%
- Mar 5, 2026Earnings: -0.26; estimate -0.2; surprise -30%
- May 7, 2026Earnings: -0.2; estimate -0.26; surprise 23.08%
- Jun 12, 2026Rating: Wedbush · Outperform → Outperform
- Jun 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 27, 2026Rating: Wedbush · Outperform → Outperform
- Aug 6, 2026Earnings: -0.18; estimate -0.20931; surprise 14%
- Aug 7, 2026Rating: Truist Securities · Buy → Buy
- Aug 19, 2026Rating: Wedbush · Outperform → Outperform
- Aug 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (81)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| RSI: Overbought | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| RSI: Overbought | Apr 27, 2026 | 6 months ago |
| RSI: Overbought | Apr 21, 2026 | 6 months ago |
| RSI: Overbought | Apr 16, 2026 | 6 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 9, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| RSI: Overbought | Mar 4, 2026 | 8 months ago |
| RSI: Overbought | Feb 25, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 19, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 9, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 27, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 2, 2026 | 10 months ago |
| RSI: Overbought | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Oct 22, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 3, 2025 | 1 year ago |
| SMA: Bullish | Oct 2, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 5, 2025 | 1 year ago |
| RSI: Overbought | Aug 20, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
| SMA: Bearish | May 20, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| MACD: Buy Signal | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 26, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
| RSI: Oversold | Dec 30, 2024 | 1 year ago |
| RSI: Oversold | Dec 16, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 760.15M
- Trailing P/E
- 0.00
- Forward P/E
- -16.92
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.28
- EPS (TTM)
- -0.82
- Beta
- 0.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -33.99M
- Total cash
- 183.12M
- Total debt
- 1.31M
- Return on equity
- -27.10%
- Shares outstanding
- 57.44M
- Short % of float
- 17.28%
- 50-day average
- 13.42
- 200-day average
- 8.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 22.86 +123.0% upside
Now 10.25
- Target (low)
- 18.00
- Target (mean)
- 22.86
- Target (high)
- 35.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.195.
Financials — quick view
CLYM Revenue — quarterly 0
CLYM Net income — quarterly -13.50M
CLYM EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.21 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.20931 | -0.18 | +0.03 | +14.00% |
| May 7, 2026 | Mar 31, 2026 | -0.26 | -0.20 | +0.06 | +23.08% |
| Mar 5, 2026 | Dec 31, 2025 | -0.20 | -0.26 | -0.06 | -30.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.16 | -0.19 | -0.03 | -18.75% |
| Aug 12, 2025 | Jun 30, 2025 | -0.19 | -0.13 | +0.06 | +31.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 19, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | main | Buy | Buy |
| Jul 27, 2026 | Wedbush | main | Outperform | Outperform |
| Jun 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2026 | Wedbush | reit | Outperform | Outperform |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- climbbio.com
News
- Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN
- Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
- Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
- Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
- Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
- Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
- Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
- Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
- Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Your note
Sign in to keep a note on CLYM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNAN AOIFE M | Chief Executive Officer | Sale | Jun 28, 2026 | 87,731 |
| PIMBLETT EMILY | Officer | Sale | Jun 19, 2025 | 18,888 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 4, 2026 | 0 |
| THOMAS STEPHEN BASIL | Director | Sale | Feb 25, 2026 | 154,657 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 19.68% | 11,300,939 | 201.61M | Jun 29, 2026 |
| FMR, LLC | 11.82% | 6,790,364 | 121.14M | Jun 29, 2026 |
| UBS Group AG | 5.93% | 3,404,866 | 60.74M | Jun 29, 2026 |
| Braidwell LP | 4.87% | 2,797,375 | 49.91M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.36% | 2,506,000 | 44.71M | Jun 29, 2026 |
| Blackrock Inc. | 4.10% | 2,354,872 | 42.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 2.56% | 1,468,417 | 26.20M | Mar 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.74% | 996,857 | 17.78M | May 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.73% | 996,400 | 17.78M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.60% | 920,068 | 16.41M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.49% | 854,986 | 15.25M | Mar 30, 2026 |
| Columbia Funds Series Trust I-Columbia Small Cap Growth Fund | 0.94% | 537,698 | 9.59M | May 30, 2026 |